Solid tumours

Cancer tumour
#Collaboration #Georgiamune #Immunotherapy #Menarini #Solid tumours #Stemline Therapeutics

Menarini and Georgiamune sign deal for oral immunotherapy

The Menarini Group and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, have announced an exclusive worldwide license and collaboration agreement with Georgiamune for GIM-621.  GIM-621 is a preclinical-stage first-in-class oral small molecule immunotherapy with potential application across multiple solid tumours.   It is one… Read More

#Business & Investment #Cancer Research #News

#Akiram Therapeutics #Immunohistochemistry #Solid tumours

First clinical results from AKIR001 to be presented at EANM 2026 

Akiram Therapeutics’ abstract presenting the first clinical results from the ongoing first-in-human trial has been selected as a Top Rated Oral Presentation (TROP) at EANM 2026. The study is evaluating 177Lu-AKIR001 in patients with irresectable or metastatic CD44v6-positive solid tumours who have no remaining standard treatment options. … Read More

#News

Map of China
#CAR-T #Cell therapy #China #Oncology #Solid tumours

When the world’s first solid-tumour CAR-T gets approved in China

In June 2026, China’s National Medical Products Administration cleared satricabtagene autoleucel (satri-cel), CARsgen’s Claudin18.2 CAR-T, for advanced gastric cancer. It became the world’s first CAR-T cell therapy approved for a solid tumour. The science is genuinely impressive. But the geography is the story. Satri-cel is not a Chinese… Read More

#Exclusive Content #Opinion #Regulatory

Tumour microenvironment
#Akiram Therapeutics #Cancer research #Drug development #Radionuclide therapy #Radiopharmaceuticals #Solid tumours

Partnership supports radiopharmaceutical solid tumour development

Akiram Therapeutics has signed an agreement with ITM for the supply of non-carrier-added lutetium-177 (n.c.a. Lu-177) to support the ongoing clinical trial of AKIR001, its lead radiopharmaceutical candidate for the treatment of solid tumours. Lu-177 is one of the most widely used medical radioisotopes in targeted radionuclide therapy and serves… Read More

#News

X-ray showing colon cancer
#Dispatch Bio #Gastrointestinal cancer #Immunotherapy #Oncology #Phase I trial #Solid tumours

New therapy targets blocks to immunotherapy success in solid tumours

Dispatch Bio has dosed the first participant in a Phase I clinical trial evaluating the safety and efficacy of DISP-10 in adult participants with advanced gastrointestinal (GI) cancers, including colorectal cancer, gastric adenocarcinoma, oesophageal adenocarcinoma, and gastroesophageal adenocarcinoma.   The participant was treated with both DV-10 and ide-cel… Read More

#Cancer Research #News

Cell and gene therapies
#Cell and gene therapy #Macrophages #Solid tumours #T-Cells

Laverock reports positive data from oncology programmes 

Laverock Therapeutics has reported in vivo functional milestones across its T-cell and macrophage oncology programmes as it advances its lead programme towards clinic.  Data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrated the company’s… Read More

#Cancer Research #News

Cancer cells
#Oncology #Phase II trial #Repertoire Immune Medicines #Solid tumours

Repertoire initiates trial of T cell-targeted immune medicine

Repertoire Immune Medicines has dosed the first participant in a Phase I/II clinical trial of RPTR-1-201, a novel TCR bispecific therapy designed to treat advanced solid tumours.   The trial is being conducted at multiple clinical sites in the United States and Europe following clearance of Repertoire’s Investigational… Read More

#Cancer Research #Editor's Choice #News

Cancer tumour
#Coiled Therapeutics #Oncology #Phase I trial #Solid tumours

First-in-class TACC3 inhibitor for solid tumours shows 80% CBR

Coiled Therapeutics has provided an update on its Phase I/II clinical trial evaluating AO-252, a first-in-class TACC3 inhibitor, in patients with advanced solid tumours.  According to the data, the transition to a Twice-Daily (BID) dosing regimen (Cohort 4b) has delivered an 80% Clinical Benefit Rate (CBR), a… Read More

#Cancer Research #News

Novartis head office
#Mergers and acquisitions #Novartis #Oncology #Solid tumours #Synnovation Therapeutics

Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion

Novartis has agreed a deal with Synnovation Therapeutics to acquire Pikavation Therapeutics and its portfolio of PI3Kα inhibitor programmes, including SNV4818.  Pikavation is a wholly-owned subsidiary of Synnovation.  SNV4818 is a potentially best-in-class pan-mutant selective PI3Kα inhibitor currently in Phase I/II clinical trials for the treatment of… Read More

#Business & Investment #News

Cancer patient receives chemotherapy via IV
#Cancer research #Clinical trial #kainova #Solid tumours

Positive results announced for metastatic tumour treatment 

A new anti-tumour treatment for metastatic solid tumours has achieved encouraging results in a Phase I clinical trial.  DT-9081, developed by biopharmaceutical company Kainova Therapeutics, is a proprietary, oral small molecule EP4 receptor (EP4R) antagonist in patients with advanced, recurrent, and metastatic solid tumours.  According to Kainova, the… Read More

#Cancer Research #News

Tumour microenvironment
#Insilico Medicine #KRAS #Oncology #Solid tumours

Insilico Medicine nominates pan-KRAS preclinical candidate

Insilico Medicine has nominated ISM6166 as a preclinical candidate, a potent, oral pan-KRAS inhibitor designed to treat a broad spectrum of solid tumours.  Among the Ras family of oncogenes, KRAS is one of the most frequently altered drivers in human cancer, playing a key role in regulating… Read More

#Cancer Research #News

#Bristol Myers Squibb #Collaboration #Janux Therapeutics #Oncology #Solid tumours

Janux and Bristol Myers Squibb partner on tumour-activated therapeutic

Bristol Myers Squibb and immunotherapy developer Janux Therapeutics have announced a collaboration and exclusive worldwide license agreement.   Under the terms of the agreement, the companies will develop an undisclosed, novel, tumour-activated therapeutic targeting a validated solid tumour antigen expressed across several human cancer types.  Janux… Read More

#Business & Investment #Cancer Research #News

Antibody drug conjugate
#Antibody drug conjugate (ADC) #China #Kelun-Biotech #NMPA #Oncology #Solid tumours

Kelun-Biotech’s ADC IND for solid tumours approved in China

Kelun-Biotech’s Investigational New Drug (IND) application for SKB105 (CR-003), an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of advanced solid tumours.  In December 2025, Kelun-Biotech and… Read More

#News #Regulatory

#Financing #Oncology #One-carbon Therapeutics #Solid tumours

One-carbon closes oversubscribed private placement financing

One-carbon Therapeutics has closed an oversubscribed 153 million SEK ($16.2 million) private placement financing round supported by current and new investors and private Swedish family offices.  The company says it will use the net proceeds from the private placement to strengthen its financial position and expand its… Read More

#Business & Investment #News